NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

抗真菌藥物市場 - 市場規模、佔有率、預測、機會分析:2021年∼2028年

Antifungal Drugs Market, by Drug Type, by Indication, by Dosage Form, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

出版商 Coherent Market Insights 商品編碼 1009423
出版日期 內容資訊 英文 164 Pages
商品交期: 2-3個工作天內
價格
抗真菌藥物市場 - 市場規模、佔有率、預測、機會分析:2021年∼2028年 Antifungal Drugs Market, by Drug Type, by Indication, by Dosage Form, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
出版日期: 2021年05月24日內容資訊: 英文 164 Pages
簡介

抗真菌藥物,用於個人真菌感染疾病的治療。灰指甲和癬等一般真菌感染疾病,通常在體外發生,不過,侵入性的真菌感染疾病,發生在身體的組織內,及肺和腦等內臟。市場主要企業,為了提高市場影響,側重於夥伴關係和契約等成長戰略。

本報告提供全球抗真菌藥物市場相關調查分析,市場動態,各市場區隔的市場分析,各地區的市場分析,競爭情形等相關的系統性資訊。

目錄

第1章 調查目的、前提條件

第2章 市場概要

第3章 市場動態、規定、趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 法規方案
  • PEST分析
  • 最近的產品銷售/核准
  • 流行病學
  • 診斷、治療概要
  • 競爭資訊
  • 處方模式
  • 醫生的偏好和見解

第4章 COVID-19的影響分析

  • 供應鏈的影響
  • 診斷、治療的影響
  • 研究開發的影響

第5章 全球抗真菌藥物市場:各藥物類型

  • 簡介
  • Echinocandins
  • Polyenes
  • 丙烯基胺
  • Azole
  • 其他

第6章 全球抗真菌藥物市場:各適應症

  • 簡介
  • 麴菌症
  • 皮膚絲狀菌症
  • 念珠菌症
  • 白黴菌症
  • 其他

第7章 全球抗真菌藥物市場:各劑型

  • 簡介
  • 粉末
  • 軟膏
  • 其他

第8章 全球抗真菌藥物市場:各地區

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第9章 競爭情形

  • 企業簡介
    • GlaxoSmithKline Plc
    • Bayer AG
    • Merck &Co., Inc
    • Enzon Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Gilead Sciences, Inc.
    • Sanofi SA
    • Astellas Pharma, Inc.
  • 分析師的見解

第10章 Section

目錄

Antifungal drugs are used to treat fungal infections in individuals. Common fungal infections such as fungal nail infection, and ringworm etc. usually occur on the external surface of the body, while certain invasive fungal infections occur inside the body tissues or inside internal organs such as lungs and brain. Fungal infection is usually associated with individuals having weak immune system, such as people suffering from HIV/AIDS. Moreover, patients undergoing chemotherapy are susceptible to invasive fungal infections. Antifungal drugs act against the fungal infections by either killing the fungal cells or by inhibiting their growth. Antifungal drugs are broadly classified as topical antifungals, oral antifungals, intravenous antifungals, and intravaginal antifungal pessaries.

Market Dynamics

Major players in the market are focused on growth strategies such as collaborations and agreements in order to enhance their market presence. For instance, in June 2017, Basilea Pharmaceutica Ltd., a biopharmaceutical company, entered into an agreement with Pfizer, Inc. and Avir Pharma, Inc. for the distribution rights of Beasilea's antifungal treatments. Pfizer will manufacture and distribute drugs for the treatment of life-threatening invasive mold infections in regions like Russia, Israel, Europe (excluding Nordics), and Turkey.

Similarly, key players in the market are focused on various business strategies such as research and development in order to expand their product portfolio. Increasing drug development is expected to drive growth of this market. For instance, in January 2019, SCYNEXIS, Inc., a biotechnology company, announced positive interim result from their first interim efficiency analysis of an ongoing FURI study. The development of this novel treatment is indicated for antifungal treatment.

Key features of the study:

  • This report provides an in-depth analysis of global antifungal drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global antifungal drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include GlaxoSmithKline Plc, Bayer AG, Abbott Laboratories, Merck & Co., Inc, Glenmark Pharmaceuticals Limited, Enzon Pharmaceuticals, Inc., Pfizer Inc., Gilead Sciences, Inc., Sanofi S.A., and Astellas Pharma, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global antifungal drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antifungal drugs market

Detailed Segmentation:

  • Global Antifungal Drugs Market, By Drug Type:
    • Echinocandins
    • Polyenes
    • Allylamines
    • Azoles
    • Others
  • Global Antifungal Drugs Market, By Indication:
    • Aspergillosis
    • Dermatophytosis
    • Candidiasis
    • Mucormycosis
    • Others
  • Global Antifungal Drugs Market, By Dosage Form:
    • Powders
    • Ointments
    • Drugs
    • Others
  • Global Antifungal Drugs Market, By Region:
    • North America
  • By Drug Type:
    • Echinocandins
    • Polyenes
    • Allylamines
    • Azoles
    • Others
  • By Indication:
    • Aspergillosis
    • Dermatophytosis
    • Candidiasis
    • Mucormycosis
    • Others
  • By Dosage Form:
    • Powders
    • Ointments
    • Drugs
    • Others
  • By Country:
    • U.S.
    • Canada
    • Latin America
  • By Drug Type:
    • Echinocandins
    • Polyenes
    • Allylamines
    • Azoles
    • Others
  • By Indication:
    • Aspergillosis
    • Dermatophytosis
    • Candidiasis
    • Mucormycosis
    • Others
  • By Dosage Form:
    • Powders
    • Ointments
    • Drugs
    • Others
  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
  • By Drug Type:
    • Echinocandins
    • Polyenes
    • Allylamines
    • Azoles
    • Others
  • By Indication:
    • Aspergillosis
    • Dermatophytosis
    • Candidiasis
    • Mucormycosis
    • Others
  • By Dosage Form:
    • Powders
    • Ointments
    • Drugs
    • Others
  • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
    • Asia Pacific
  • By Drug Type:
    • Echinocandins
    • Polyenes
    • Allylamines
    • Azoles
    • Others
  • By Indication:
    • Aspergillosis
    • Dermatophytosis
    • Candidiasis
    • Mucormycosis
    • Others
  • By Dosage Form:
    • Powders
    • Ointments
    • Drugs
    • Others
  • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
    • Middle East
  • By Drug Type:
    • Echinocandins
    • Polyenes
    • Allylamines
    • Azoles
    • Others
  • By Indication:
    • Aspergillosis
    • Dermatophytosis
    • Candidiasis
    • Mucormycosis
    • Others
  • By Dosage Form:
    • Powders
    • Ointments
    • Drugs
    • Others
  • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • By Drug Type:
    • Echinocandins
    • Polyenes
    • Allylamines
    • Azoles
    • Others
  • By Indication:
    • Aspergillosis
    • Dermatophytosis
    • Candidiasis
    • Mucormycosis
    • Others
  • By Dosage Form:
    • Powders
    • Ointments
    • Drugs
    • Others
  • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
  • GlaxoSmithKline Plc *
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Bayer AG
  • Abbott Laboratories
  • Merck & Co., Inc
  • Glenmark Pharmaceuticals Limited
  • Enzon Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Gilead Sciences, Inc.
  • Sanofi S.A.
  • Astellas Pharma, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Indication
    • Market Snippet, By Dosage Form
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Regulatory Scenario
  • PEST Analysis
  • Recent Product Launch/Approval
  • Epidemiology
  • Diagnosis and Treatment Overview
  • Competitive Intelligence
  • Prescription Pattern
  • Physicians Preferences and Views

4. COVID - 19 Impact Analysis

  • Impact on Supply Chain
  • Impact on Diagnosis and Treatment
  • Impact on Research and Development

5. Global Antifungal Drugs Market, By Drug Type, 2017-2028 (US$ Million)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Echinocandins
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Polyenes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Allylamines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Azoles
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Antifungal Drugs Market, By Indication, 2017 - 2028 (US$ Million)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Aspergillosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Dermatophytosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Candidiasis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Mucormycosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Antifungal Drugs Market, By Dosage Form, 2017 - 2028 (US$ Million)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Powders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Ointments
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global Antifungal Drugs Market, By Region, 2017 - 2028 (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Indication, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Dosage Form, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Type , 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Indication, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Dosage Form, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Indication, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Dosage Form, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type , 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Dosage Form , 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Drug Type , 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Dosage Form , 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Type , 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Dosage Form , 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

  • Company Profiles
    • GlaxoSmithKline Plc
    • Company Overview
    • Drug Type Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Bayer AG
    • Company Overview
    • Drug Type Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Merck & Co., Inc
    • Company Overview
    • Drug Type Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Enzon Pharmaceuticals, Inc.
    • Company Overview
    • Drug Type Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Pfizer Inc.
    • Company Overview
    • Drug Type Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Gilead Sciences, Inc.
    • Company Overview
    • Drug Type Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Sanofi S.A.
    • Company Overview
    • Drug Type Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Astellas Pharma, Inc.
    • Company Overview
    • Drug Type Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact